Tags

Type your tag names separated by a space and hit enter

Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.

Abstract

Chronic myeloid leukemia (CML) is caused by the Bcr-Abl oncoprotein,the product of the t(9;22) chromosomal translocation that generates the Philadelphia chromosome. Different disease phenotypes are associated with each of the three Bcr-Abl isoforms: p190Bcr-Abl, p210Bcr-Abl, and p230Bcr-Abl all of which have a constitutively activated tyrosine kinase. Mechanisms associated with malignant transformation include altered cellular adhesion, activation of mitogenic signaling pathways, inhibition of apoptosis, and proteasomal degradation of physiologically important cellular proteins.CML is subject to an inexorable progression from an "indolent" chronic phase to a terminal blast crisis. Disease progression is presumed to be associated with the phenomenon of genomic instability.

Links

  • Publisher Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Haematology, Imperial College, London & Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. j.melo@imperial.ac.uk

    Source

    Hematology/oncology clinics of North America 18:3 2004 Jun pg 545-68, vii-viii

    MeSH

    Cell Transformation, Neoplastic
    Fusion Proteins, bcr-abl
    Humans
    Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    Oncogene Proteins
    Signal Transduction
    Translocation, Genetic

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    15271392

    Citation

    Melo, Junia V., and Michael W N. Deininger. "Biology of Chronic Myelogenous Leukemia--signaling Pathways of Initiation and Transformation." Hematology/oncology Clinics of North America, vol. 18, no. 3, 2004, pp. 545-68, vii-viii.
    Melo JV, Deininger MW. Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation. Hematol Oncol Clin North Am. 2004;18(3):545-68, vii-viii.
    Melo, J. V., & Deininger, M. W. (2004). Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation. Hematology/oncology Clinics of North America, 18(3), pp. 545-68, vii-viii.
    Melo JV, Deininger MW. Biology of Chronic Myelogenous Leukemia--signaling Pathways of Initiation and Transformation. Hematol Oncol Clin North Am. 2004;18(3):545-68, vii-viii. PubMed PMID: 15271392.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation. AU - Melo,Junia V, AU - Deininger,Michael W N, PY - 2004/7/24/pubmed PY - 2004/9/24/medline PY - 2004/7/24/entrez SP - 545-68, vii-viii JF - Hematology/oncology clinics of North America JO - Hematol. Oncol. Clin. North Am. VL - 18 IS - 3 N2 - Chronic myeloid leukemia (CML) is caused by the Bcr-Abl oncoprotein,the product of the t(9;22) chromosomal translocation that generates the Philadelphia chromosome. Different disease phenotypes are associated with each of the three Bcr-Abl isoforms: p190Bcr-Abl, p210Bcr-Abl, and p230Bcr-Abl all of which have a constitutively activated tyrosine kinase. Mechanisms associated with malignant transformation include altered cellular adhesion, activation of mitogenic signaling pathways, inhibition of apoptosis, and proteasomal degradation of physiologically important cellular proteins.CML is subject to an inexorable progression from an "indolent" chronic phase to a terminal blast crisis. Disease progression is presumed to be associated with the phenomenon of genomic instability. SN - 0889-8588 UR - https://www.unboundmedicine.com/medline/citation/15271392/Biology_of_chronic_myelogenous_leukemia__signaling_pathways_of_initiation_and_transformation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0889858804000139 DB - PRIME DP - Unbound Medicine ER -